References
- Van den Bossche H, Willemsens G, Cools W, et al. Biochemical effects of miconazole on fungi II. Inhibition of ergosterol biosynthesis in. Candida albicans. Chem Biol Interact 1978; 21: 59–78
- Van den Bossche H, Willemsens G, Cools W, et al. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob Agents Chemother 1980; 17: 922–8
- Schuster I. The interaction of representative members from two classes of antimycotics-the azoles and the allylamines with cytochrome P-450 in steroidogenic tissues and liver. Xenobiotica 1985; 15: 529–46
- Sheets J J, Mason J I. Ketoconazole: A potent inhibitor of cytochrome P-450 dependent drug metabolism in rat liver. Drug Metab Dispos 1984; 12: 603–6
- Sheets J J, Mason J I, Wise C A, et al. Inhibition of rat liver microsomal cytochrome P-450 steroid hydroxylase reaction by imidazole antimycotic agents. Biochem Pharmacol 1986; 35: 487–91
- Back D J, Tija J F. Inhibition of tolbutamide metabolism by substituted imidazole drugs in vivo: evidence for a structure-activity relationship. Br J Pharmacol 1985; 85: 121–6
- Back D J, Tija J F, Karbwang J, et al. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharmacol 1988; 26: 23–9
- Lavrijsen K, Van Houdt J, Thijs D, et al. Interaction of miconazole, ketoconazole and itraconazole with rat liver microsomes. Xenobiotica 1987; 17: 45–57
- Schuster I. Potential of allylamines to inhibit cytochrome P-450. Recent trends in the discovery, development and evaluation of antifungal drugs, R A Fromtling. JR Prous, Barcelona 1987; 471–8
- Purba H S, Maggs J L, Orme M L'E, et al. The metabolism of 17α-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. Br J Clin Pharmacol 1987; 23: 447–53
- Omura T, Sato R. The carbon monoxide binding pigment of liver microsomes. J Biol Chem 1964; 239: 2370–8
- Lowry O H, Rosebrough N J, Farr A L, et al. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265–75
- Back D J, Stevenson P, Tija J F. Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutarnide ethinyloestradiol. cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br J Clin Pharmacol 1989; 28: 166–70
- Miners J O, Smith K J, Robson R A, et al. Tolbutamide hydroxylation by human liver microsomes. Kinetic chardcterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol 1988; 37: 1137–44
- Knodell R G, Hall B D, Wilkinson G R, et al. Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J Pharmacol Exp Ther 1987; 241: 1112–19
- Guengerich F P. Oxidation of 17α-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 1988; 33: 500–8
- Ball S E, Forrester L, Wolf C R, et al. Characterisation of the form(s) of cytochrome P-450 involved in oestrogen 2–hydroxylation. Br J Pharmacol 1988; 94: 449
- Kronbach T, Fischer V, Meyer U A. Cyclosporine metabolism in human liver. Identification of a cytochrome P-450 III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630–5
- Cockburn I, Cyclosporine A. A clinical evaluation of drug interactions. Transplant Proc 1986; 18: 50–5
- Dieperink H, Molter J. Ketoconazole and cyclosporine. Lancet 1982; ii: 1217
- Ferguson R M, Sutherland D ER, Simmons R L, et al. Ketoconazole, cyclosporine metabolism and renal transplantation. Lancet 1982; ii: 882–3